IFNG and head and neck squamous cell carcinoma: Similar results were found after IFN-γ stimulation, where pembrolizumab and pembrolizumab plus cetuximab led to positive effects in only 6 out of 23 and cetuximab in 10 out of 23 HNSCC cases.